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to determine what tasks were conducted by pharmacy staff and
how much time was spent in the preparation of the top ﬁfteen
chemotherapeutic drugs and regimens used across the four sites.
Pharmacy staff was observed as to the time spent in each task
relative to the total time in an average shift to determine the pro-
portion of total work hours dedicated to the preparation of the
selected chemotherapy drugs. RESULTS: The total average ﬁxed
costs for the preparation of chemotherapy doses across all sites
was $36.03 (range $32.08 for Virginia and $67.19 for Utah).
Data from the four centers was projected to the 3,990,495
million estimated chemotherapy infusions administered to a
national Medicare population in 2003 resulting in a total annual
cost to Medicare for chemotherapy preparation of
$143,777,535. Pharmacists were observed to spend the major-
ity of their day (90% or higher) on tasks directly related to the
preparation of these agents. CONCLUSIONS: Preparation costs
for chemotherapy are signiﬁcant and need to be considered in
determining reimbursement rates for administration.
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OBJECTIVES: To estimate the per-patient cost of hospital care
associated with the treatment of breast cancer recurrence in the
UK. METHODS: Patient-level resource utilisation data for 571
node-positive early breast cancer patients treated at the Western
general Hospital, Edinburgh between 1991 and 2004, of whom
180 experienced disease recurrence, were analysed in order to
provide estimates of the cost of hospital care post-relapse. Unit
costs from national sources were applied to patient-level resource
use data for hospital care collected over a period of ﬁve years
post-relapse. The total cost was estimated by bootstrapping
(1000 simulations; with replacement). RESULTS: Of the 180
patients who experienced a relapse, 145 (81%) died within
follow-up, 143 of these due to breast cancer. The ﬁrst relapse
was distant in 145 patients and locoregional in 35 (25 of which
experienced a subsequent distant disease and 3 experienced
further locoregional recurrence within follow-up). The bootstrap
mean cost post-relapse (and 95% conﬁdence intervals) was
£14,085 (£12,370–£15,877) for patients whose ﬁrst relapse was
distant and £14,575 (£11,411–£17,872) for patients whose ﬁrst
relapse was locoregional. Comparison with previous published
estimates suggests that the cost of chemotherapy treatments has
increased substantially in recent years. CONCLUSIONS: Hos-
pital costs for patients with relapsed breast cancer may be higher
than previously estimated, perhaps due to recent increases in the
costs of chemotherapy agents. Costs for patients whose ﬁrst
relapse is locoregional are similar on average to that for patients
whose ﬁrst relapse is distant, as many have subsequent locore-
gional or distant relapses.
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OBJECTIVES: The aim of this study is to calculate the market
share of drug cost from the total health insurance cost of treat-
ment of breast, cervical and colorectal cancer. DATA AND
METHODS: Data derives from the central, nationwide database
of the Hungarian National Health Insurance Fund Administra-
tion (OEP) covering the year 2001. The cost of treatment
includes the cost of outpatient care, the acute and chronic inpa-
tient care, the (subsidies) of medicines’ prices (reimbursement)
and the expenditure on disability to work. The subsidies of drugs
include the following ATC codes: “L” (Antineoplastic and
immunomodulating agents), “N02” (Analgesics) and “A04”
(Antiemetics and antineuseants). The diseases were identiﬁed
with the following ICD (International Classiﬁcation of diseases):
breast (C50, D05, D24), cervix (C53, D06, D26.0) colorectal
(C18, C19, C20, C21, D01.0, D01.1, D01.2, D01.3, D01.4,
D12). RESULTS: The total health insurance cost of treatment of
breast cancer was around 33.4 million € (8.6 billion Hungarian
forint) in 2001. The total health insurance cost of treatment of
cervical cancer was around €4.1 million (1 billion Hungarian
forint) in 2001. The total health insurance cost of treatment of
colorectal cancer was around €38.871.666 (9.98 billion Hun-
garian forints) in 2001. The drug cost of breast cancer was €9.45
million, cervical cancer €0.62 million and colorectal cancer was
€4.86 million. The market share of drug reimbursement cost
from the total health insurance cost was the following: breast
cancer (28.3%), cervical cancer (15.4%), colorectal cancer
(12.5%). CONCLUSIONS: The health insurance reimbursement
of drugs varies in different types of cancer. The drug costs rep-
resent the highest cost element in breast cancer compared to cer-
vical and colorectal cancer.
PCN31
COST EFFECTIVENESS MODEL OF IV BISPHOSPHONATES IN
THE PREVENTION OF BONE COMPLICATIONS IN BREAST
CANCER PATIENTS WITH BONE METASTASES: A GERMAN
INPATIENT PERSPECTIVE
Botteman M1, Hay J2, Stephens JM1, Barghout V3, Quednau K4
1Pharmerit North America LLC, Bethesda, MD, USA; 2University of
Southern California, Los Angeles, CA, USA; 3Novartis Pharmaceuticals
Corporation, Florham Park, NJ, USA; 4Novartis Pharma GmbH,
Nuernberg, Germany
OBJECTIVES: Intravenous (IV) bisphosphonates reduce skeletal
related events (SREs) and alleviate bone pain in patients with
breast cancer and bone metastases (BCBM). However, these
agents differ in terms of efﬁcacy, administration time and costs.
We compared the cost-effectiveness of IV bisphosphonates from
a German inpatient perspective. METHODS: A 7-year literature-
based model was designed to simulate the natural history, costs
and quality-adjusted life expectancy (QALE) of 4 hypothetical
cohorts of BCBM patients receiving no treatment (NT) or
monthly IV ibandronate (IB), pamidronate (PA) or zoledronic
acid (ZA). The model included probabilities of death and disease
progression and the risk of SREs. The risk reduction in SREs
with each bisphosphonate was estimated using the Andersen Gill
hazard ratio v. NT (0.71 for IB, 0.70 for PA, and 0.56 for ZA).
The model included direct medical costs for drugs, IV adminis-
tration and SREs. Survival was adjusted for the time spent with
and without SREs and on and off therapy to capture the bis-
phosphonates’ impact on QALE. All outcomes were discounted
at 5% per annum. RESULTS: The cumulative number of SREs
over the 7-year simulation was lowest for ZA (3.53 per patient),
followed by PA (4.17), IB (4.21) and NT (5.80). Average QALE
was highest with ZA (1.10), followed by PA (1.09), IB (1.09)
and NT (0.92). Total per-patient costs were lowest for ZA
(€15,520), followed by PA (€16,968), NT (€17,317) and IBN
(€17,881). In probabilistic sensitivity analyses, the 95th per-
centile value for the cost per QALY saved was €15,600 (ZA),
€84,000 (IB), and €87,500 (PA). ZA, PA and IB were cost savings
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vs. NT in 79%, 56%, and 36% of model runs, respectively.
CONCLUSIONS: For the management of BCBM patients, ZA
is the preferred bisphosphonate as it is more effective and less
expensive than other IV agents or even no therapy.
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OBJECTIVES: The primary core analysis of the BIG 1–98 study
showed that in postmenopausal women with hormone receptor
positive (HR+) early breast cancer, the aromatase inhibitor (AI)
letrozole (LET) signiﬁcantly reduced the risk of recurrence by
19% overall (95% CI 7–30%) and the risk of relapse in distant
sites by 27% overall (CI 12–40%) compared with tamoxifen
(TAM). Letrozole demonstrated non-signiﬁcant improvements in
overall survival and contralateral breast cancer. LET patients had
reduced risks of endometrial cancer and venous thromboem-
bolism (VTE), but increased risks of mild/moderate hypercho-
lesteraemia, cardiac events and fractures. This study reports the
cost-effectiveness of initial adjuvant therapy with LET vs. TAM
in postmenopausal women with HR+ early stage breast cancer
from the UK NHS perspective based on preliminary analyses of
published results of the BIG 1–98 trial. METHODS: A Markov
model describes the occurrence of contralateral tumours; locore-
gional recurrence; soft tissue, bone, and visceral metastases, and
treatment side effects (endometrial cancer, VTE, hip fractures,
other fractures, hypercholesterolaemia, and MI). Clinical para-
meters for TAM were based on published results of the BIG 1–98
trial and other published studies, as were health-state utilities.
Corresponding probabilities for LET were calculated by apply-
ing RRs for LET vs. TAM from the BIG 1–98 study. Costs of
breast-cancer care were estimated using UK patient-level
resource use data. Lifetime costs (2004UK£) and QALYs were
estimated for HR+ women aged 61 years at diagnosis, dis-
counted at 3.5% annually. RESULTS: Compared with TAM,
LET results in an additional 0.33 QALYs (12.84 vs. 12.51).
These beneﬁts are obtained at an additional cost of £4079
(£12,474 vs. £8395). Cost-effectiveness of LET vs. TAM is
£12,321 (95% CI £2672-£23,889) per QALY saved. CON-
CLUSION: Adjuvant treatment with letrozole is cost-effective
from a UK NHS perspective compared with tamoxifen and
should be considered in women diagnosed with HR+ early breast
cancer.
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OBJECTIVE: TS-1 is a newly developed oral anticancer drug.
We previously reported the treatment costs for gastric cancer in
Japan and suggested that TS-1 is cost saving compared to con-
ventional intravenous chemotherapy. The aim of this study is to
examine health utilities in gastric cancer patients and to assess
the cost-utility of TS-1. METHODS: Patients with advanced or
recurrent gastric cancer who were able to ingest meals were 
identiﬁed retrospectively from the ordering system database of
Showa University Hospital between January 1998 and July
2001. The utilities of the patients during chemotherapy were
assessed by oncology pharmacists on the basis of medical records
(including information on mobility, meal ingestion, pain, and
other symptoms), using the rating scale method, time trade-off
method, standard gamble method and EQ-5D mapping proce-
dure. The costs of the patients were calculated on the basis of
hospital billing data. Cost-utility analysis was conducted from a
societal perspective. RESULTS: Of the 23 patients who met the
inclusion criteria, 13 received TS-1 and 10 received conventional
intravenous chemotherapy. Mean (SD) utilities as measured by
the rating scale method, time trade-off method, standard gamble
method and EQ-5D mapping procedure were 0.89 (0.12), 0.90
(0.11), 0.94 (0.07), and 0.84 (0.18), respectively, in the TS-1
group. The corresponding utilities in the conventional intra-
venous chemotherapy group were 0.65 (0.18), 0.66 (0.18), 0.81
(0.12), and 0.52 (0.23), respectively. The utilities of the TS-1
were signiﬁcantly (P < 0.05) higher than those of conventional
intravenous chemotherapy by every technique. The mean
monthly cost during chemotherapy was signiﬁcantly lower in the
TS-1 group than in the conventionalintravenous chemotherapy
group (€2481 vs. €6458, P < 0.05). CONCLUSION: TS-1, an
oral anticancer agent, is a dominant strategy with a lower cost
and a greater health outcome than conventional intravenous
chemotherapy in patients with advanced or recurrent gastric
cancer.
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OBJECTIVES: In the Arimidex, Tamoxifen Alone or in Combi-
nation (ATAC) trial, anastrozole produced signiﬁcantly longer
disease-free survival and time to recurrence compared with
tamoxifen in hormone receptor-positive (HR+) postmenopausal
women with early breast cancer after 5 years of treatment.
(ATAC Trialists’ Group. Lancet 2005;365:60–2) Based on these
ATAC results, the cost-utility of anastrozole versus tamoxifen is
estimated from the perspective of the UK National Health
Service (NHS). METHODS: A Markov model and Weibull sur-
vival curves ﬁtted to trial data were used to project 5-year out-
comes from the ATAC trial to an actuarial time point of 25 years.
Resource utilisation data were obtained primarily from a physi-
cian survey. Unit costs (2003–4 UK£) were obtained from routine
NHS sources. Utility scores for relevant health states were
obtained from 26 representative UK patients, using a standard
gamble technique. Costs and beneﬁts were discounted at the
annual rate of 3.5%. All effectiveness and cost parameters
subject to uncertainty were varied in a probabilistic analysis.
Incremental cost effectiveness ratios (ICERs), 95% CIs, and
acceptability curves were calculated. RESULTS: The estimated
25 year ICER of anastrozole compared with generic tamoxifen
was £7811 (£219–31,438) per QALY gained with a probability
of the order of 90% that it lies below £20,000 per QALY gained.
The results were sensitive to the time horizon of the model and
